Enzolytics (Enzolytics) ROCE % : 0.00% (As of Jun. 2011)

View and export this data going back to 2008. Start your Free Trial

What is Enzolytics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enzolytics's annualized ROCE % for the quarter that ended in Jun. 2011 was 0.00%.

Enzolytics ROCE % Historical Data

The historical data trend for Enzolytics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzolytics ROCE % Chart

Enzolytics Annual Data

Trend

Dec07

Jul08

Dec09

Dec10

ROCE %

Enzolytics Quarterly Data
	Sep07	Dec07	Apr08	Jul08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11
ROCE %	Get a 7-Day Free Trial										-	-	-	-	-

Enzolytics ROCE % Calculation

Enzolytics's annualized ROCE % for the fiscal year that ended in Dec. 2010 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2010 )		(A: Dec. 2009 )		(A: Dec. 2010 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2010 )		(A: Dec. 2009 )		(A: Dec. 2010 )
	=	-7.445	/	( ( (0.085 - 1.274)	+	(0.153 - 0.677) )	/ 2 )
	=	-7.445	/	( (-1.189	+	-0.524)	/ 2 )
	=	-7.445	/	-0.8565
	=	869.24 %

Enzolytics's ROCE % of for the quarter that ended in Jun. 2011 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2011 )		(Q: Mar. 2011 )		(Q: Jun. 2011 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2011 )		(Q: Mar. 2011 )		(Q: Jun. 2011 )
	=	-0.856	/	( ( (0.137 - 0.776)	+	(0.112 - 0.778) )	/ 2 )
	=	-0.856	/	( ( -0.639	+	-0.666 )	/ 2 )
	=	-0.856	/	-0.6525
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2011) EBIT data.

Enzolytics (OTCPK:ENZC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enzolytics ROCE % Related Terms

Thank you for viewing the detailed overview of Enzolytics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzolytics (Enzolytics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzolytics Inc (OTCPK:ENZC) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013

Website

https://www.enzolytics.com

Enzolytics Inc is a biotechnology company, whose products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies, and an artificial intelligence (AI) platform for health care developments. It has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus.